- Home
- VNDA vs XFOR Comparison
VNDA vs XFOR Comparison
Compare VNDA & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNDA | XFOR |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.1M | 288.5M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VNDA | XFOR |
|---|---|---|
| Price | $4.04 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $11.75 | $11.60 |
| AVG Volume (30 Days) | 841.3K | ★ 880.2K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $216,105,000.00 | $6,500,000.00 |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $35.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.72 | ★ 150.00 |
| 52 Week Low | $4.01 | $2.43 |
| 52 Week High | $9.91 | $4.83 |
Technical Indicators
Market Signals| Indicator | VNDA | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 22.64 | 34.19 |
| Support Level | N/A | N/A |
| Resistance Level | $5.37 | $4.40 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 4.66 | 34.40 |
Price Performance
Historical ComparisonAbout VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.